They Just Don't Get...
Health Care: Drugs
EntreMed Inc. (ENMD: NASDAQ)
$2.03 0.07 | 3.57%
06/04/12 - 03:59 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.96 |
| 52 Week High | 4.85 |
| 52 Week Low | 0.90 |
| Avg. Daily Vol. (Mil) | 0.02 |
| Beta (3 year) | 1.53 |
| Share Related Items | |
| Mkt Cap (Mil) | 44.11 |
| Shares Out (Mil) | 22.50 |
| Float (Mil) | 12.10 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.20 |
| Current Ratio | 1.20 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 22.72 |
| Price/Book | 0.00 |
| Price/Cash Flow | -8.10 |
| Per Share Data | |
| Earnings | -0.46 |
| Sales | 0.09 |
| Book Value | 0.00 |
| Cash Flow | -0.24 |
| Business Summary | |
|---|---|
| EntreMed, Inc. is a clinical-stage pharmaceutical company, which develops therapeutic candidates for the treatment of cancer and inflammation. | |
| General Information | |
| 9640 Medical Center Drive
Rockville, MD 20850 |
|
| www.entremed.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 7 | |
| CEO: Dr. Ken Keyong Ren | |
| Short Interest | |
| Current Month (Mil) | 0.12 |
| Previous Month (Mil) | 0.13 |
| Short Interest Ratio (Days) | 6.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -37.50 |
| Return on Investments | -185.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ENMD
- Portfolio NameUser Type
- Contributor6 Drug Stocks Unworthy of B...
- UserBeaver
- Contributor10 Stocks Under $5 Outperfo...
- ContributorStocks Under $5 at Risk of ...
- UserDorkingLad Portfolio 1
- Usersmallbiz
- Usersteves #1
- UserThe Investment Psychologist...
- Userdrweik Portfolio 1
- UserJake's Portfolio 1
Latest ENMD Headlines from TheStreet
- 6 Drug Stocks Unworthy of Biotech Bull Market 02.07.12 | 12:02 pm
- 5 Stocks Under $10 Poised for Big Upside 02.03.12 | 02:02 pm
- 10 Stocks Under $5 Outperforming in 2012 01.31.12 | 05:01 am
- Stocks Under $5 at Risk of Bankruptcy 06.08.11 | 06:06 am
- Biotech Sector Weekly Rewind 11.20.10 | 08:11 am
- Stock Offerings: Two Harbors 04.19.10 | 10:04 am
- Sprint Nextel, Palm: Early Volume Plays 04.19.10 | 07:04 am
- ThermoGenesis, Power-One: Early Volume Plays 02.05.10 | 07:02 am
- Netlist, EntreMed: Midday Volume Plays 12.14.09 | 02:12 pm
- ExpressJet, Entremed: Midday Volume Plays 11.16.09 | 02:11 pm
Press Releases for ENMD
- EntreMed Appoints Interim CEO - PR Newswire 04.03.12 | 07:04 am
- EntreMed Initiates Plans For China Office - PR Newswire 03.05.12 | 02:03 pm
- EntreMed Completes Strategic Financing - PR Newswire 02.06.12 | 07:02 am
- Biotech Leaders Wei-Wu He, Ph.D And Tak W. Mak, Ph.D Join EntreMed's Board Of Directors - PR Newswire 02.06.12 | 07:02 am
- EntreMed's ENMD-2076 Demonstrates Promising Activity In A Phase 2 Study In Platinum-Resistant Ovarian Cancer Patients - PR Newswire 10.03.11 | 07:10 am
- EntreMed Enters Into $7.5 Million Equity Facility And Initiates $1.1 Million Drawdown - PR Newswire 06.28.11 | 05:06 pm
- Selected Value Therapeutics Exercises Right To Develop And Commercialize Enmd-2076 In China - PR Newswire 06.07.11 | 11:06 am
- EntreMed's ENMD-2076 Demonstrates Clinical Activity In Recurrent, Platinum-Resistant Ovarian Cancer Patients - PR Newswire 06.03.11 | 03:06 pm
- EntreMed Reports Fourth Quarter And Year-End 2009 Financial Results - PR Newswire 03.29.10 | 04:03 pm
Partner Headlines for ENMD
- China Biotech In Review: GSK Explores All Paths To Increase China Presence - Seeking Alpha 03.11.12 | 07:03 am
- China Biotech Week in Review: Shanghai Pharma Plans $1.2 Billion IPO - Seeking Alpha 09.12.10 | 09:09 am
- Big Pharma Looks to Biotech for Innovation - Seeking Alpha 09.12.10 | 08:09 am
- EntreMed Widens Loss in 2Q, Clinical Trials for Ovarian Cancer Progress - Fox Business 08.16.10 | 12:08 pm
